This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
A drug developed to treat erectile dysfunction might seem an unlikely treatment for Alzheimer's disease. But researchers are increasingly interested in whether medicines such as Viagra could also help protect the brain.
These drugs affect blood flow and other processes that may play a role in brain health. An experimental drug called AR1001 has produced encouraging results in a large international clinical trial.
In one group of people with early Alzheimer's, the drug was reported to slow the worsening of symptoms by 31% over a year, compared with a placebo.
AriBio, a South Korean biotechnology company, announced the results at the 19th Clinical Trials on Alzheimer's Disease conference in Boston, U.S. A full scientific paper, reviewed by other researchers, has not yet been published.
The phase 3 trial—the final phase of testing in humans—involved 1,535 people with early Alzheimer's in 13 countries. Participants took either 30 mg of AR1001 or a placebo every day for a year.
Researchers measured changes in memory, thinking and everyday activities. They looked at two groups: everyone who took part in the trial and a smaller group of 604 people who were not taking other Alzheimer's medicines to ease their symptoms, such as donepezil or memantine.
Only this smaller group saw a 31% reduction in worsening symptoms. Across the whole trial, AR1001 did not produce reliable benefits.
Erectile dysfunction drugs work by blocking an enzyme that normally breaks down a chemical messenger—called cGMP—in the body.
Source link







